Trial Profile
A Double-blind, Randomized, Placebo Controlled, Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Japanese Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs GSK 2230672 (Primary)
- Indications Cholestasis; Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 26 Jun 2022 Results from three Phase 1 studies 114985,116511, 205808 and from patients with PBC in two Phase 2 stud, 201000 and other study, presented at The International Liver Congress 2022
- 08 Nov 2016 Status changed from recruiting to completed.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.